Simcere Completes Enrollment for Phase III Study of CDK4/6 Inhibitor in mTNBC
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the completion of first-line enrollment for its...
Simcere Pharmaceutical
Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278
China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with...
Simcere Pharma’s H1 2022 Revenue Rises 27% on New Drug Sales, R&D Push
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) reported RMB 2.7 billion (USD 391 million) in...
Hansoh Pharma Licenses GHDDI’s GDI-4405 for Global Development in COVID-19
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with the Global...
Simcere’s Trilaciclib Wins NMPA Approval for Chemotherapy Myeloprotection
Jiangsu Simcere Pharmaceutical Co., Ltd’s trilaciclib has received marketing approval from the National Medical Products...